OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Ronald H. Spair sold 510,112 shares of OraSure Technologies stock in a transaction on Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now owns 208,606 shares in the company, valued at approximately $4,309,799.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) opened at 20.26 on Friday. OraSure Technologies, Inc. has a 52 week low of $6.87 and a 52 week high of $21.59. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 37.45 and a beta of 1.57. The stock has a 50 day moving average of $18.98 and a 200-day moving average of $14.50.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. The company had revenue of $40.18 million during the quarter, compared to the consensus estimate of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $0.07 EPS. Equities research analysts expect that OraSure Technologies, Inc. will post $0.48 earnings per share for the current year.
OSUR has been the topic of a number of recent analyst reports. Stephens reiterated an “overweight” rating and issued a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. BidaskClub lowered shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Saturday, May 6th. Jefferies Group LLC boosted their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Finally, Canaccord Genuity boosted their price objective on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $15.46.
Several institutional investors have recently added to or reduced their stakes in OSUR. Advisory Services Network LLC increased its position in OraSure Technologies by 1,419.2% in the second quarter. Advisory Services Network LLC now owns 12,913 shares of the medical instruments supplier’s stock worth $223,000 after buying an additional 12,063 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in OraSure Technologies during the second quarter worth approximately $5,119,000. Koch Industries Inc. acquired a new position in OraSure Technologies during the second quarter worth approximately $216,000. Piedmont Investment Advisors LLC acquired a new position in OraSure Technologies during the second quarter worth approximately $216,000. Finally, 361 Capital LLC increased its position in OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 10,107 shares during the last quarter. 89.76% of the stock is owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.